Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Luminex, BD combine for cancer diagnostics

This article was originally published in Clinica

Executive Summary

Luminex has partnered with BD Diagnostics’ TriPath subsidiary to develop, market and sell new biomarker-based diagnostic tests for early-stage detection of certain cancers. The two firms have signed a development and supply agreement under which the new technology will be developed using Luminex’s multiplexing xMAP platform. This allows scientists to conduct multiple tests simultaneously on one patient sample. Financial details of the partnership were not revealed. According to Austin, Texas-based Luminex, the survival rate of women diagnosed with ovarian cancer at an early stage is more than 90%, compared to 20-30% when the disease is detected at a later stage.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel